Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.31 |
| ▸ | CRHBP | P24387 | 2/20 | 0.31 |
| ▸ | CRHR2 | Q13324 | 2/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2204951 | 1.00 | LMNA (0.31) | LMNACRHBPCRHR2SMN1; SMN2HTT | |
| SCHEMBL5525170 | 0.67 | ABCG2 (0.36) | LMNACRHBPCRHR2SMN1; SMN2HTT | |
| SCHEMBL30334802 | 0.67 | LMNA (0.43) | LMNACRHBPCRHR2SMN1; SMN2HTT | |
| SCHEMBL1304032 | 0.67 | CYP2A6 (0.31) | — | |
| SCHEMBL121647 | 0.67 | LMNA (0.43) | LMNACRHBPCRHR2SMN1; SMN2HTT | |
| Hydrochloric Acid SCHEMBL11520836 | 0.64 | LMNA (0.41) | LMNACRHBPCRHR2SMN1; SMN2HTT | |
| SCHEMBL219574 | 0.64 | — | — | |
| SCHEMBL996383 | 0.62 | — | — | |
| Cyclohexane SCHEMBL23674790 | 0.60 | SMN1; SMN2 (0.43) | LMNACRHBPCRHR2SMN1; SMN2HTT | |
| SCHEMBL577897 | 0.58 | MAOA (0.42) | LMNACRHBPCRHR2SMN1; SMN2HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230228684-A1 | METHODS AND SYSTEMS FOR SPATIALLY IDENTIFYING ABNORMAL CELLS | LUMICELL, INC. (US) | 2023-07-20 | — | — | US | disclosed |
| US-11592396-B2 | Methods and systems for spatially identifying abnormal cells | LUMICELL, INC. (US) | 2023-02-28 | — | — | US | disclosed |
| EP-2618849-B1 | MULTIVALENT FLUORESCENT PROBES | CALIPER LIFE SCIENCES INC (US) | 2020-10-21 | — | — | EP | disclosed |
| EP-3695853-A1 | MOLECULAR IMAGING PROBES AND THEIR COMPOSITIONS | Lumicell Diagnostics, Inc. (US) | 2020-08-19 | — | — | EP | disclosed |
| US-20200225160-A1 | METHODS AND SYSTEMS FOR SPATIALLY IDENTIFYING ABNORMAL CELLS | LUMICELL, INC. (US) | 2020-07-16 | — | — | US | disclosed |
| EP-2646057-B1 | METHODS AND SYSTEMS FOR SPATIALLY IDENTIFYING ABNORMAL CELLS | LUMICELL INC (US) | 2020-03-18 | — | — | EP | disclosed |
| US-9289515-B2 | Multivalent fluorescent probes | CALIPER LIFE SCIENCES (US) | 2016-03-22 | — | — | US | disclosed |
| US-20160025632-A1 | METHODS AND SYSTEMS FOR SPATIALLY IDENTIFYING ABNORMAL CELLS | LUMICELL, INC. (US) | 2016-01-28 | — | — | US | disclosed |
| US-9155471-B2 | Methods and systems for spatially identifying abnormal cells | Lumicell, Inc'. (US) | 2015-10-13 | — | — | US | disclosed |
| US-20150209450-A1 | MULTIVALENT FLUORESCENT PROBES | PERKINELMER INC (US) | 2015-07-30 | — | — | US | disclosed |
| US-20110104071-A1 | METHODS AND SYSTEMS FOR SPATIALLY IDENTIFYING ABNORMAL CELLS | LUMICELL DIAGNOSTICS, INC. (US) | 2011-05-05 | — | — | US | disclosed |
| US-20110021908-A1 | METHODS AND SYSTEMS FOR SPATIALLY IDENTIFYING ABNORMAL CELLS | LUMICELL DIAGNOSTICS, INC. (US) | 2011-01-27 | — | — | US | disclosed |
| WO-2010138738-A1 | METHODS AND SYSTEMS FOR SPATIALLY IDENTIFYING ABNORMAL CELLS | LUMICELL DIAGNOSTICS, INC. (US) | 2010-12-02 | — | — | WO | disclosed |
| US-20050214221-A1 | Optical imaging probes | VISEN MEDICAL, INC. (US) | 2005-09-29 | — | — | US | disclosed |
| EP-1485716-A1 | OPTICAL IMAGING PROBES | Visen Medical, Inc. (US) | 2004-12-15 | — | — | EP | disclosed |
| EP-1428858-A1 | Hydrophilic marker dyes based on benzopyrylo-polymethines | Dyomics GmbH (DE) | 2004-06-16 | — | — | EP | disclosed |
| EP-1273584-B1 | 2- or 4-Chromenyliden based merocyanines and use thereof | DYOMICS GMBH (DE) | 2004-02-18 | — | — | EP | disclosed |
| WO-2003079015-A1 | OPTICAL IMAGING PROBES | VISEN MEDICAL, INC. (US) | 2003-09-25 | — | — | WO | disclosed |
| EP-1273584-A1 | 2- or 4-Chromenyliden based merocyanines and use thereof | Dyomics GmbH (DE) | 2003-01-08 | — | — | EP | disclosed |
| EP-1273584-A1 | 2- or 4-Chromenyliden based merocyanines and use thereof | Dyomics GmbH (DE) | 2003-01-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150209450-A1 | MULTIVALENT FLUORESCENT PROBES | CHERP, CD2BP2, DNM1L | LMNA 2386/4885CRHBP 2578/4885CRHR2 4041/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.